Chemotherapeutic drugs sensitize pre-B ALL cells for CD95- and cytotoxic T-lymphocyte-mediated apoptosis

Leukemia

Volumn 13, Issue 3, 1999, Pages 400-409

  Posovszky, C ^a   Friesen, C ^b   Herr, I ^a   Debatin, K M ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

Apoptosis; B lineage ALL; CD95 (APO 1 Fas); Cytotoxic drugs

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CYTARABINE; DOXORUBICIN; FAS ANTIGEN; MERCAPTOPURINE; METHOTREXATE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL X;

ACUTE LYMPHOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CANCER CHEMOTHERAPY; CELL DEATH; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HOMEOSTASIS; HUMAN; HUMAN CELL; LYMPHOCYTE; LYMPHOKINE ACTIVATED KILLER CELL; MITOCHONDRION; PRE B LYMPHOCYTE; PRIORITY JOURNAL; SENSITIZATION;

EID: 0033013231     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401327     Document Type: Article

References (52)

1. Kaufmann SH. Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note. Cancer Res 1989; 49: 5870-5878.
2. Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metast Rev 1992; 11: 121-139.
3. Huschtscha L, Bartier W, Ross C, Tattersall M. Characteristics of cancer cell death after exposure to cytotoxic drugs in vitro. Br J Cancer 1996; 73: 54-60.
4. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly(ADP-ribose)polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 1993; 53: 3976-3985.
5. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/FAS) receptor/Iigand system in drug-induced apoptosis in leukemia cells. Nature Med 1996; 2: 574-577.
6. Nagata S, Golstein P. The fas death factor. Science 1995; 267: 1449-1456.
7. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989; 169: 1747-1756.
8. Trauth BC, Klas C, Peters AM, Matzku S, Moller P, Falk W, Debatin KM, Krammer PH. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301-305.
9. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169-1678.
10. Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C, Schmidt A, Debatin KM, Krammer PH, Moller P. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993; 69: 415-429.
11. Owen-Schaub LB, Meterissian S, Ford RJ. Fas/APO-1 expression and function on malignant cells of hematologic and nonhematologic origin. J Immunther 1993; 14: 234-241.
12. DiGiuseppe JA, LeBeau P, Augenbraun J, Borowitz MJ. Multiparameter flow-cytometric analysis of bcl-2 and Fas expression in normal and neoplastic hematopoiesis. J Clin Pathol 1996; 106: 345-351.
13. Nishiuchi R, Yoshino T, Matsuo Y, Sakuma I, Cao L, Seino Y, Takahashi K, Akagi T. The Fas antigen is detected on immature B cells and the representative cell lines show Fas-mediated apoptosis. Br J Haematol 1996; 92: 302-307.
14. Mandik L, Nguyen K-AT, Erikson J. Fas receptor expression on B-lineage cells. Eur J Immunol 1995; 25: 3148-3154.
15. Karawajew L, Wuchter C, Ruppert V, Drexler H, Gruss HJ, Dörken B, Ludwig WD. Differential CD95 expression and function in T and B lineage acute lymphoblastic leukemia cells. Leukemia 1997; 11: 1245-1252.
16. Debatin KM, Krammer PH. Resistance to APO-1 (CD95) induced apoptosis in T-ALL is determined by a BCL-2 independent anti-apoptotic program. Leukemia 1995; 9: 815-820.
17. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) (see comments). Nature 1995; 373: 438-441.
18. Daniel PT, Krammer PH. Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. J Immunol 1994; 152: 5624-5632.
19. Fulda S, Sieverts H, Friesen C, Herr I, Debatin KM. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. Cancer Res 1997; 57: 3823-3829.
20. Mueller M, Strand S, Hug H, Heinemann EM, Walczak H, Hofmann WJ, Stremmel W, Krammer PH, Galle PR. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J Clin Invest 1997; 99: 403-413.
21. Friesen C, Fulda S, Debatin KM. Deficient activation of CD95(APO-1/Fas) system in drug-resistant cells. Leukemia 1997; 11: 1833-1841.
22. Landowski TH, Gleason-Guzman MC, Dalton WS. Selection for drug resistance results in resistance to Fas-mediated apoptosis. Blood 1997; 89: 1854-1861.
23. Lee KL, Spielmann J, Zhao DJ, Olsen KJ, Podack ER. Perform, fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells. J Immunol 1996; 157: 1919-1925.
24. Knight CRL, Rees RC, Platts A, Johnson T, Griffin M. Interleukin-2-activated human effector lymphocytes mediate cytotoxicity by inducing apoptosis in human leukaemia and solid tumour target cells. J Immunol 1993; 79: 535-541.
25. Classen CF, Fulda S, Friesen C, Debatin KM. Decreased sensitivity of drug-resistant cells towards T cell cytotoxicity. Leukemia (in press).
26. Nakamura S, Takeshima M, Nakamura Y, Ohtake S, Matsuda T. Induction of apoptosis in HL60 leukemic cells by anticancer drugs in combination with anti-Fas monoclonal antibody. Anticancer Res 1997; 17: 137-180.
27. Weller M, Winter S, Schmidt C, Esser P, Fontana A, Dichgans J, Groscurth P. Topoisomerase-I inhibitors for human malignant glioma: differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and β-lapachone. Int J Cancer 1997; 73: 707-714.
28. Micheau O, Solary E, Hammann A, Martin F, Dimanche Boitrel MT. Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity. J Natl Cancer Inst 1997; 89: 783-789.
29. Morimoto H, Yonehara S, Bonavida B. Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins. Cancer Res 1993; 53: 2591-2596.
30. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84: 1415-1420.
31. Naito M, Nagashima K, Mashima T, Tsuruo T. Phosphatidylserine externalization is a downstream event of interleukin-1-b-converting enzyme family protease activation during apoptosis. Blood 1997; 89: 2060-2066.
32. Beltinger CP, Böhler T, Karawajew L, Ludwig WD, Schrappe M, Debatin KM. Mutation analysis of CD95 (APO-1/Fas) in childhood B-lineage acute lymphoblastic leukemia. Br J Haematol 1998; 102: 722-728.
33. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME, Dixit VM. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 1996; 85: 817-827.
34. Herr I, Balemanns L, Böhler T, Walczak H, Debatin KM. Monitoring of CD95(APO-1/Fas) ligand expression in human T cells by quantitative RT-PCR. Cell Death Diff 1996; 3: 299-305.
35. Muller C, Chatelut E, Gualano V, De Forni M, Huguet F, Attal M, Canal P, Laurent G. Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: comparison of bolus administration and continuous infusion. Cancer Chemother Pharmacol 1993; 32: 379-384.
36. Rustum YM, Raymakers RAP. 1-β-Arabinofuranosylcytosine in therapy of leukemia: preclinical and clinical overview. Pharma Ther 1992; 56: 307-321.
37. Ramilo-Torno LV, Avramis VI. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines. Cancer Chemother Pharmacol 1995; 35: 191-199.
38. Buchholz B, Frei E, Eisenbarth J, Weigand M, Ludwig R. Time course of methotrexate polyglutamate formation and degradation in the pre-B-leukaemia cell line Nalm6 and in lymphoblasts from children with leukaemia. Eur J Cancer 1996; 32A: 2101-2107.
39. Los M, Van de Craen M, Penning LC, Schenk H, Westendorp M, Baeuerle PA, Dröge W, Krammer PH, Fiers W, Schulze-Osthoff K. Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis. Nature 1995; 375: 81-83.
40. Los M, Herr I, Friesen C, Fulda S, Schulze-Osthoff K, Debatin KM. Crossresistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). Blood 1997; 90: 3118-3129.
41. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS, Dixit VM. Yama/CPP32β, a mammalian homologue of CED-3, is a crm A-inhibitable protease that cleaves the death substrate poly(ADP-ribose)polymerase. Cell 1995; 81: 801-809.
42. Kroemer G, Zamzami N, Susin SA. Mitochondrial control of apoptosis. Immunol Today 1997; 18: 44-51.
43. Decaudin D, Geley S, Hirsch T, Castedo M, Marchetti P, Macho A, Kofler R, Kroemer G. Bcl-2 and Bcl-XL antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res 1997; 57: 62-67.
44. Medema JP, Scaffidi C, Krammer PH, Peter ME. Bcl-xL acts downstream of caspase-8 activation by the CD95 death-inducing signaling complex. J Biol Chem 1998: 273: 3388-3393.
45. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH, Peter ME. Two CD95 (APO-1/Fas) signaling pathways. EMBO J 1998; 17: 1675-1687.
46. Montel AH, Bochan MR, Hobbs JA, Lynch DH, Brahmi Z. Fas involvement in cytotoxicity mediated by human NK cells. Cell Immunol 1995; 166: 236-246.
47. +-independent T cell-mediated cytotoxicity. J Exp Med 1993; 177: 195-200.
48. Fulda S, Los M, Friesen C, Debatin KM. Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system. Int J Cancer 1998; 76: 105-144.
49. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-365.
50. Levy Y, Benglagha K, Buzyn A, Colombel M, Brouet J-C, Lassoued K. IL-7 sensitizes human pre-B cells but not pro-B cells to Fas/APO-1 (CD95)-mediated apoptosis. Clin Exp Immunol 1997; 110: 329-335.
51. Schneider TJ, Grillot D, Foote L, Nunez GE, Rothstein TL. Bcl-x protects primary B cells against Fas-mediated apoptosis. J Immunol 1997; 59: 4834-4839.
52. Golstein P. Controlling cell death. Science 1997; 275: 1081-1082.